Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
BUY NOW OR PAY MORE LATER !!!!!
Puramed (PMBS.OB)
Market Cap: 18 Mio$
Price: 1,51 $
Shares Out : 11,99 M (8,6 M Shares held by Insider)
Float : 2,6 Million
Why Puramed Bioscience Inc. (PMBS.OB) Should Be On Your Radar
PuraMed Bioscience, Inc. is a pharmaceutical company focused on developing and marketing a line of new, non-prescription medicines. These products target major consumer health needs, including the treatment of headaches, insomnia, and general pain. The company aims launch its first retail products within six months, and then leverage that success to become a leader in the Over-the-Counter (OTC) medicine marketplace.
Although PuraMed Bioscience is entering into a competitive market, the company’s products promise to bring innovation to the industry, allowing for faster absorption into the blood stream, greater effectiveness, fewer side effects, and lower dosage requirements. The first three products the company plans to introduce include: LipiGesic M™ (for acute relief of migraine headaches), LipiGesic H™ (for acute relief of tension headaches) and LipiGesic PM™ (for insomnia).
PuraMed is already sufficiently funded via private funding and ready to move forward with the execution of its comprehensive business plan. Recently BrokerBank analyst Philip Wright, CFA initiated investment coverage of the company and has rated the company as a “speculative buy”. Wright praised the company for running on a lean basis by keeping salaries reasonable and office overhead costs extremely low.
The share structure of the stock is also attractive with only 7,929,246 shares of common stock outstanding as of last month. PuraMed is also a fully reporting company, meaning the company must be audited by a PCAOB registered public accounting firm and must comply with the requirements of Sarbanes-Oxley. These requirements allow for greater transparency and the ability to attract a larger investor audience, subsequently enhancing shareholder value and providing greater access to capital for further growth.
With a management team bringing more than 80 years of combined industry experience, a product line addressing major healthcare needs with many competitive advantages, and a well thought-out business plan, this company is well on its way to success in the multi-billion dollar OTC medicine market. Continue to watch this company as it strives to dramatically improve the quality of life for millions of Americans.
About the Company
PuraMed was established to capture two unique opportunities. The first is to build a substantial and profitable business, rapidly, beginning with three products developed by its founders: LipiGesic™ M (for acute relief of migraine headaches), LipiGesic™ H(for acute relief of tension headaches) and PuraMed™ PM (for insomnia). Each of these is effective and addresses a very large OTC consumer market, collectively well over $2 billion in the U.S. Each product will be unique in its class .
UNDER RADAR...
http://www.cpexpharm.com/files/pdfs/fs/factsheet.pdf
Cpex Pharma (CPEX)
Market Cap : 23 Mio$
Cash : 14,8 Mio$
Price : 9,16 $
Shares Out : 2,53 M
Pipeline
http://www.cpexpharm.com/pipeline.htm
Insider activity
http://finance.yahoo.com/q/it?s=CPEX
Third-Quarter Highlights
For the third quarter of 2009 compared to the third quarter of 2008;
* Revenues increased 26% to $5.0 million from $3.9 million.
* Operating expenses increased 17% to $5.8 million from $5.0 million.
* Net loss was $872,000, or $0.34 per share, compared to $1.0 million, or $0.43 per share.
The growth in revenues for the third quarter of 2009 was due to increased royalties on sales of Testim®. This growth is due to a reported 17% increase in prescriptions for Testim during the third quarter of 2009 compared to the same period in 2008. Operating expenses in the third quarter of 2009 increased $853,000, primarily due to clinical trial expenses associated with CPEX’s ongoing NasulinTM clinical program and legal costs associated with its on-going litigation with Upsher-Smith Laboratories regarding Testim. These increases were partially offset by a decrease in share-based compensation expense. Operating expenses for the three months ended September 30, 2008 include a $1.2 million non-cash charge resulting from the modification of equity awards associated with the spin-off from Bentley.
Business Update
Ongoing Clinical Trials: CPEX’s intranasal insulin product candidate for the treatment of hyperglycemia in patients with Type 1 and Type 2 diabetes, Nasulin, is continuing clinical trials evaluating the safety and efficacy profile of the product. CPEX has completed screening activities in a Phase 2a study designed to assess the efficacy and safety of Nasulin versus placebo over a 6-week treatment period. This study is being conducted at multiple centers in the U.S. Prior trials in patients with Type 1 or 2 diabetes, as well as in healthy volunteers, have indicated that Nasulin appears to have an ultra-rapid time/action profile which has the potential to mimic more closely the body’s natural insulin response to meals.
Partnering Update: Following the completion of an End-of-Phase-2 meeting earlier this year, Serenity Pharmaceuticals, CPEX’s licensing and development partner, recently began recruiting patients in multiple Phase 3 clinical trials with their undisclosed urology drug delivered using CPEX’s intranasal technology for the treatment of nocturia. These randomized, double blind, placebo controlled studies are being conducted at multiple sites in the United States.
New Patents Issued: On October 27, 2009 the United States Patent and Trademark Office issued six additional patents that expand the scope and claims of CPEX’s original patent covering Testim®, 1% testosterone gel. Testim® is marketed by Auxilium under license from CPEX. The new patents will expire in April 2023 and are listed in Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the Orange Book), published by the U.S. Food and Drug Administration.
Management Comments
“We are pleased about the recent completion of screening activities in our current Phase 2a study and the continued progress of our Nasulin clinical program. We look forward to presenting data from our earlier trials at the Ninth Annual Diabetes Technology Meeting taking place this week in San Francisco” stated John A. Sedor, CPEX President and Chief Executive Officer. “We are also encouraged by Serenity’s advancement of their compound for the treatment of nocturia into Phase 3 studies. This drug addresses a large urology indication with few treatment options. This is an exciting opportunity for CPEX and Serenity and we look forward to updating you on the future of this program.”
RALLLYYYYYYY UP 60%
LIPIGESIC (MIGRAINE) LAUNCH WITHIN 2 WEEKS = 10 BAGGER EASILY .PLEASE DO YOUR OWN RESEARCH!!
GLTA ..This stock is under Radar !!! GET IN NOW !!!
Puramed (PMBS.OB)
Market Cap: 20 Mio$
Price: 1,70 $
Shares Out : 11,99 M (8,6 M Shares held by Insider)
Float : 2,6 Million
Why Puramed Bioscience Inc. (PMBS.OB) Should Be On Your Radar
PuraMed Bioscience, Inc. is a pharmaceutical company focused on developing and marketing a line of new, non-prescription medicines. These products target major consumer health needs, including the treatment of headaches, insomnia, and general pain. The company aims launch its first retail products within six months, and then leverage that success to become a leader in the Over-the-Counter (OTC) medicine marketplace.
Although PuraMed Bioscience is entering into a competitive market, the company’s products promise to bring innovation to the industry, allowing for faster absorption into the blood stream, greater effectiveness, fewer side effects, and lower dosage requirements. The first three products the company plans to introduce include: LipiGesic M™ (for acute relief of migraine headaches), LipiGesic H™ (for acute relief of tension headaches) and LipiGesic PM™ (for insomnia).
PuraMed is already sufficiently funded via private funding and ready to move forward with the execution of its comprehensive business plan. Recently BrokerBank analyst Philip Wright, CFA initiated investment coverage of the company and has rated the company as a “speculative buy”. Wright praised the company for running on a lean basis by keeping salaries reasonable and office overhead costs extremely low.
The share structure of the stock is also attractive with only 7,929,246 shares of common stock outstanding as of last month. PuraMed is also a fully reporting company, meaning the company must be audited by a PCAOB registered public accounting firm and must comply with the requirements of Sarbanes-Oxley. These requirements allow for greater transparency and the ability to attract a larger investor audience, subsequently enhancing shareholder value and providing greater access to capital for further growth.
With a management team bringing more than 80 years of combined industry experience, a product line addressing major healthcare needs with many competitive advantages, and a well thought-out business plan, this company is well on its way to success in the multi-billion dollar OTC medicine market. Continue to watch this company as it strives to dramatically improve the quality of life for millions of Americans.
About the Company
PuraMed was established to capture two unique opportunities. The first is to build a substantial and profitable business, rapidly, beginning with three products developed by its founders: LipiGesic™ M (for acute relief of migraine headaches), LipiGesic™ H(for acute relief of tension headaches) and PuraMed™ PM (for insomnia). Each of these is effective and addresses a very large OTC consumer market, collectively well over $2 billion in the U.S. Each product will be unique in its class .
RALLLLLLLLLLLYYYYYYYY
FOR NEWBIES .
LIPIGESIC (MIGRAINE) LAUNCH WITHIN 2 WEEKS = 10 BAGGER EASILY .PLEASE DO YOUR OWN RESEARCH!!
GLTA ..This stock is under Radar !!!
Puramed (PMBS.OB)
Market Cap: 20 Mio$
Price: 1,70 $
Shares Out : 11,99 M (8,6 M Shares held by Insider)
Float : 2,6 Million
Why Puramed Bioscience Inc. (PMBS.OB) Should Be On Your Radar
PuraMed Bioscience, Inc. is a pharmaceutical company focused on developing and marketing a line of new, non-prescription medicines. These products target major consumer health needs, including the treatment of headaches, insomnia, and general pain. The company aims launch its first retail products within six months, and then leverage that success to become a leader in the Over-the-Counter (OTC) medicine marketplace.
Although PuraMed Bioscience is entering into a competitive market, the company’s products promise to bring innovation to the industry, allowing for faster absorption into the blood stream, greater effectiveness, fewer side effects, and lower dosage requirements. The first three products the company plans to introduce include: LipiGesic M™ (for acute relief of migraine headaches), LipiGesic H™ (for acute relief of tension headaches) and LipiGesic PM™ (for insomnia).
PuraMed is already sufficiently funded via private funding and ready to move forward with the execution of its comprehensive business plan. Recently BrokerBank analyst Philip Wright, CFA initiated investment coverage of the company and has rated the company as a “speculative buy”. Wright praised the company for running on a lean basis by keeping salaries reasonable and office overhead costs extremely low.
The share structure of the stock is also attractive with only 7,929,246 shares of common stock outstanding as of last month. PuraMed is also a fully reporting company, meaning the company must be audited by a PCAOB registered public accounting firm and must comply with the requirements of Sarbanes-Oxley. These requirements allow for greater transparency and the ability to attract a larger investor audience, subsequently enhancing shareholder value and providing greater access to capital for further growth.
With a management team bringing more than 80 years of combined industry experience, a product line addressing major healthcare needs with many competitive advantages, and a well thought-out business plan, this company is well on its way to success in the multi-billion dollar OTC medicine market. Continue to watch this company as it strives to dramatically improve the quality of life for millions of Americans.
About the Company
PuraMed was established to capture two unique opportunities. The first is to build a substantial and profitable business, rapidly, beginning with three products developed by its founders: LipiGesic™ M (for acute relief of migraine headaches), LipiGesic™ H(for acute relief of tension headaches) and PuraMed™ PM (for insomnia). Each of these is effective and addresses a very large OTC consumer market, collectively well over $2 billion in the U.S. Each product will be unique in its class .
A real BIG Opportunity !!!
CPEX's Nasulin Insulin Therapy Featured in an Oral Presentation and Four Abstracts at the Ninth Annual Diabetes Technology Meeting
* Press Release
* Source: CPEX Pharmaceuticals, Inc.
* On 9:51 am EST, Thursday November 5, 2009
EXETER, N.H.--(BUSINESS WIRE)--CPEX Pharmaceuticals, Inc. (NASDAQ: CPEX - News) today announced that its intranasal insulin product candidate, NasulinTM, will be featured in an oral presentation and four abstracts at the Ninth Annual Diabetes Technology Meeting, November 5-7, 2009 at the Hyatt Regency Airport in San Francisco, California. Dr. Lance Berman, Senior Vice President and Chief Medical Officer, is scheduled to deliver an oral presentation entitled “The Technology and Clinical Aspects of Nasal Insulin Therapy” at 9:30 a.m. PST on Saturday, November 7. Further details on the abstracts are provided below.
A Randomized 6-Way Crossover Study of NasulinTM, Saline and Lispro in Subjects with Type 2 Diabetes to Determine Optimum Dose Timing
A similar glucose-lowering effect may be achieved by administering Nasulin either just before or at the end of the meal offering more flexibility of dosing than with injectable insulins.
Two Randomized Crossover Glucose Clamp Studies of NasulinTM and Lispro
In both Type1 diabetic patients and healthy volunteers, peak glucose metabolism rates occurred earlier with ultra-rapid acting Nasulin than with rapid acting lispro. The pharmacodynamic profile indicates Nasulin has optimum activity when glucose levels rise during a meal with less potential for hypoglycemia in the hours after the meal has ended.
Dose-Exposure for Single and Dual Nostril Administration of Nasal Insulin (NasulinTM)
The findings from this study demonstrated significantly enhanced insulin absorption when a 50 IU dose is administered as 2 sprays of 25 IU given in the same nostril rather than one spray in each nostril. In addition, the study also demonstrated that nasal administration of up to 200 microliters per nostril was well tolerated allowing the administration of doses up to 100 IU. Together these findings provide an improved dosing methodology and a higher maximum dose for evaluation in future clinical trials.
Dose-Exposure for Two Dose Strengths of Nasal Insulin (NasulinTM)
These data demonstrated that the original Nasulin concentration (1.0%) and the new concentration (0.7%) revealed proportional dose-dependent increases in insulin exposures.
Dr. Berman commented, “The data from these studies provide important information on Nasulin’s ability to rapidly lower glucose following a meal. With the completion of each study, we gain additional insight into the potential benefits Nasulin could offer to patients with diabetes. The most exciting aspect of these results is the second dose concentration, which will provide subjects in future clinical trials with a wider dose range to individually titrate their insulin needs to maximize glucose reduction without increasing the risk of hypoglycemia. These potential advantages of Nasulin’s ultra-rapid time-action profile may provide treating physicians and their patients safer alternatives for controlling their diabetes.”
Big news coming soon ...
“We are pleased about the recent completion of screening activities in our current Phase 2a study and the continued progress of our Nasulin clinical program. We look forward to presenting data from our earlier trials at the Ninth Annual Diabetes Technology Meeting taking place this week in San Francisco” stated John A. Sedor, CPEX President and Chief Executive Officer
Cheapest Bio-Stock on Nasdaq ....
This stock is under Radar .Do your own Research .
Cpex Pharma (CPEX)
Market Cap : 23,4 Mio$
Cash : 14,8 Mio$
Price : 9,27 $
Shares Out : 2,53 M
Pipeline
http://www.cpexpharm.com/pipeline.htm
Insider activity
http://finance.yahoo.com/q/it?s=CPEX
Third-Quarter Highlights
For the third quarter of 2009 compared to the third quarter of 2008;
* Revenues increased 26% to $5.0 million from $3.9 million.
* Operating expenses increased 17% to $5.8 million from $5.0 million.
* Net loss was $872,000, or $0.34 per share, compared to $1.0 million, or $0.43 per share.
The growth in revenues for the third quarter of 2009 was due to increased royalties on sales of Testim®. This growth is due to a reported 17% increase in prescriptions for Testim during the third quarter of 2009 compared to the same period in 2008. Operating expenses in the third quarter of 2009 increased $853,000, primarily due to clinical trial expenses associated with CPEX’s ongoing NasulinTM clinical program and legal costs associated with its on-going litigation with Upsher-Smith Laboratories regarding Testim. These increases were partially offset by a decrease in share-based compensation expense. Operating expenses for the three months ended September 30, 2008 include a $1.2 million non-cash charge resulting from the modification of equity awards associated with the spin-off from Bentley.
Business Update
Ongoing Clinical Trials: CPEX’s intranasal insulin product candidate for the treatment of hyperglycemia in patients with Type 1 and Type 2 diabetes, Nasulin, is continuing clinical trials evaluating the safety and efficacy profile of the product. CPEX has completed screening activities in a Phase 2a study designed to assess the efficacy and safety of Nasulin versus placebo over a 6-week treatment period. This study is being conducted at multiple centers in the U.S. Prior trials in patients with Type 1 or 2 diabetes, as well as in healthy volunteers, have indicated that Nasulin appears to have an ultra-rapid time/action profile which has the potential to mimic more closely the body’s natural insulin response to meals.
Partnering Update: Following the completion of an End-of-Phase-2 meeting earlier this year, Serenity Pharmaceuticals, CPEX’s licensing and development partner, recently began recruiting patients in multiple Phase 3 clinical trials with their undisclosed urology drug delivered using CPEX’s intranasal technology for the treatment of nocturia. These randomized, double blind, placebo controlled studies are being conducted at multiple sites in the United States.
New Patents Issued: On October 27, 2009 the United States Patent and Trademark Office issued six additional patents that expand the scope and claims of CPEX’s original patent covering Testim®, 1% testosterone gel. Testim® is marketed by Auxilium under license from CPEX. The new patents will expire in April 2023 and are listed in Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the Orange Book), published by the U.S. Food and Drug Administration.
Management Comments
“We are pleased about the recent completion of screening activities in our current Phase 2a study and the continued progress of our Nasulin clinical program. We look forward to presenting data from our earlier trials at the Ninth Annual Diabetes Technology Meeting taking place this week in San Francisco” stated John A. Sedor, CPEX President and Chief Executive Officer. “We are also encouraged by Serenity’s advancement of their compound for the treatment of nocturia into Phase 3 studies. This drug addresses a large urology indication with few treatment options. This is an exciting opportunity for CPEX and Serenity and we look forward to updating you on the future of this program.”
LIPIGESIC(MIGRAINE)LAUNCH WITHIN 6 WEEKS = RALLY VERY SOON.
GET IN NOW WHILE ITS VERY VERY CHEAP HERE !!!
Puramed (PMBS.OB)
Market Cap: 12,45 Mio$
Price: 1,04 $
Shares Out : 11,99 M (8,6 M Shares held by Insider)
Float : 2,6 Million
Why Puramed Bioscience Inc. (PMBS.OB) Should Be On Your Radar
Monday, April 6th, 2009
PuraMed Bioscience, Inc. is a pharmaceutical company focused on developing and marketing a line of new, non-prescription medicines. These products target major consumer health needs, including the treatment of headaches, insomnia, and general pain. The company aims launch its first retail products within six months, and then leverage that success to become a leader in the Over-the-Counter (OTC) medicine marketplace.
Although PuraMed Bioscience is entering into a competitive market, the company’s products promise to bring innovation to the industry, allowing for faster absorption into the blood stream, greater effectiveness, fewer side effects, and lower dosage requirements. The first three products the company plans to introduce include: LipiGesic M™ (for acute relief of migraine headaches), LipiGesic H™ (for acute relief of tension headaches) and LipiGesic PM™ (for insomnia).
PuraMed is already sufficiently funded via private funding and ready to move forward with the execution of its comprehensive business plan. Recently BrokerBank analyst Philip Wright, CFA initiated investment coverage of the company and has rated the company as a “speculative buy”. Wright praised the company for running on a lean basis by keeping salaries reasonable and office overhead costs extremely low.
The share structure of the stock is also attractive with only 7,929,246 shares of common stock outstanding as of last month. PuraMed is also a fully reporting company, meaning the company must be audited by a PCAOB registered public accounting firm and must comply with the requirements of Sarbanes-Oxley. These requirements allow for greater transparency and the ability to attract a larger investor audience, subsequently enhancing shareholder value and providing greater access to capital for further growth.
With a management team bringing more than 80 years of combined industry experience, a product line addressing major healthcare needs with many competitive advantages, and a well thought-out business plan, this company is well on its way to success in the multi-billion dollar OTC medicine market. Continue to watch this company as it strives to dramatically improve the quality of life for millions of Americans.
About the Company
PuraMed was established to capture two unique opportunities. The first is to build a substantial and profitable business, rapidly, beginning with three products developed by its founders: LipiGesic™ M (for acute relief of migraine headaches), LipiGesic™ H(for acute relief of tension headaches) and PuraMed™ PM (for insomnia). Each of these is effective and addresses a very large OTC consumer market, collectively well over $2 billion in the U.S. Each product will be unique in its class.
Migraine drug launch will hapen very soon..
Dont miss the big Opportunity
Puramed (PMBS.OB)
Market Cap: 12 Mio$
Price: 1 $
Shares Out : 11,99 M (8,6 M Shares held by Insider)
Float : 2,6 Million
Why Puramed Bioscience Inc. (PMBS.OB) Should Be On Your Radar
Monday, April 6th, 2009
PuraMed Bioscience, Inc. is a pharmaceutical company focused on developing and marketing a line of new, non-prescription medicines. These products target major consumer health needs, including the treatment of headaches, insomnia, and general pain. The company aims launch its first retail products within six months, and then leverage that success to become a leader in the Over-the-Counter (OTC) medicine marketplace.
Although PuraMed Bioscience is entering into a competitive market, the company’s products promise to bring innovation to the industry, allowing for faster absorption into the blood stream, greater effectiveness, fewer side effects, and lower dosage requirements. The first three products the company plans to introduce include: LipiGesic M™ (for acute relief of migraine headaches), LipiGesic H™ (for acute relief of tension headaches) and LipiGesic PM™ (for insomnia).
PuraMed is already sufficiently funded via private funding and ready to move forward with the execution of its comprehensive business plan. Recently BrokerBank analyst Philip Wright, CFA initiated investment coverage of the company and has rated the company as a “speculative buy”. Wright praised the company for running on a lean basis by keeping salaries reasonable and office overhead costs extremely low.
The share structure of the stock is also attractive with only 7,929,246 shares of common stock outstanding as of last month. PuraMed is also a fully reporting company, meaning the company must be audited by a PCAOB registered public accounting firm and must comply with the requirements of Sarbanes-Oxley. These requirements allow for greater transparency and the ability to attract a larger investor audience, subsequently enhancing shareholder value and providing greater access to capital for further growth.
With a management team bringing more than 80 years of combined industry experience, a product line addressing major healthcare needs with many competitive advantages, and a well thought-out business plan, this company is well on its way to success in the multi-billion dollar OTC medicine market. Continue to watch this company as it strives to dramatically improve the quality of life for millions of Americans.
About the Company
PuraMed was established to capture two unique opportunities. The first is to build a substantial and profitable business, rapidly, beginning with three products developed by its founders: LipiGesic™ M (for acute relief of migraine headaches), LipiGesic™ H(for acute relief of tension headaches) and PuraMed™ PM (for insomnia). Each of these is effective and addresses a very large OTC consumer market, collectively well over $2 billion in the U.S. Each product will be unique in its class.
Do not sell any shares... Buy on dips!
PMBS.OB will be a huge Winner soon ...
Read..
http://www.puramedbioscience.com/PuraMed%20Power%20Point%20FINAL%208-14-09.ppt
Do not sell any shares... Buy on dips!
This Stock will be a huge Winner soon ....
Last Chance to buy under 2$ !!!
Market-Cap 18 Mio$
Price 1,74 $
When does PuraMed BioScience expect to launch its first commercial product and begin generating revenue?
PuraMed BioScience will launch its LipiGesic M migraine product via a direct-response infomercial scheduled for broadcast in October 2009.
********************************************
When do you anticipate generating revenue?
PuraMed BioScience expects to generate revenue in October 2009, which corresponds to the date the direct response commercial is scheduled to be televised.
******************************************
When do you expect to launch first product in retail or commercial environment?
PuraMed BioScience will approach retailers within 60-days from the initial airing of our LipiGesic M migraine product direct response television commercial.
*******************************************
Do PuraMed BioScience products require FDA approval
Unlike prescription drugs or medications, non-prescription healthcare remedies such as PuraMed products do not require FDA approval prior to entering the market. PuraMed products are nonetheless subject to substantial FDA and other federal regulations governing their use, labeling, advertising, manufacturing and ingredients. PuraMed BioScience believes that its current and proposed development, formulation, marketing and other practices and procedures will comply fully with all governmental regulations applicable to PuraMed products.
*******************************
How many products does PuraMed BioScience have in progress?
Last Chance to buy under 2$ !!!
Market-Cap 18 Mio$
Price 1,74 $
When does PuraMed BioScience expect to launch its first commercial product and begin generating revenue?
PuraMed BioScience will launch its LipiGesic M migraine product via a direct-response infomercial scheduled for broadcast in October 2009.
********************************************
When do you anticipate generating revenue?
PuraMed BioScience expects to generate revenue in October 2009, which corresponds to the date the direct response commercial is scheduled to be televised.
******************************************
When do you expect to launch first product in retail or commercial environment?
PuraMed BioScience will approach retailers within 60-days from the initial airing of our LipiGesic M migraine product direct response television commercial.
*******************************************
Do PuraMed BioScience products require FDA approval
Unlike prescription drugs or medications, non-prescription healthcare remedies such as PuraMed products do not require FDA approval prior to entering the market. PuraMed products are nonetheless subject to substantial FDA and other federal regulations governing their use, labeling, advertising, manufacturing and ingredients. PuraMed BioScience believes that its current and proposed development, formulation, marketing and other practices and procedures will comply fully with all governmental regulations applicable to PuraMed products.
*******************************
How many products does PuraMed BioScience have in progress?
LipiGesic M for the relief of migraine headaches is the first PuraMed product that will be introduced to the market. Following its entrance into the market, two other products, LipiGesic PM for insomnia and LipiGesic H for tension headaches, will be developed and introduced. There are also product formulations for relief from canker sores, restless-leg syndrome, nighttime-reflux disorders, smoking cessation, and weight loss that will soon follow.
BOOOOOYAAAAAHHHHHHHH
MARKET-CAP OF 18 Mio$ IS STILL WAYYYYYYYY UNDERVALUED ..
Get on board before the stock gets discovered . 6 US$++ soon !!!
Puramed (PMBS.OB)
Market Cap: 18 M$
Price: 1,50 $
Shares Out : 11,99 M (8,6 M Shares held by Insider)
Float : 2,6 Million
Why Puramed Bioscience Inc. (PMBS.OB) Should Be On Your Radar
Monday, April 6th, 2009
PuraMed Bioscience, Inc. is a pharmaceutical company focused on developing and marketing a line of new, non-prescription medicines. These products target major consumer health needs, including the treatment of headaches, insomnia, and general pain. The company aims launch its first retail products within six months, and then leverage that success to become a leader in the Over-the-Counter (OTC) medicine marketplace.
Although PuraMed Bioscience is entering into a competitive market, the company’s products promise to bring innovation to the industry, allowing for faster absorption into the blood stream, greater effectiveness, fewer side effects, and lower dosage requirements. The first three products the company plans to introduce include: LipiGesic M™ (for acute relief of migraine headaches), LipiGesic H™ (for acute relief of tension headaches) and LipiGesic PM™ (for insomnia).
PuraMed is already sufficiently funded via private funding and ready to move forward with the execution of its comprehensive business plan. Recently BrokerBank analyst Philip Wright, CFA initiated investment coverage of the company and has rated the company as a “speculative buy”. Wright praised the company for running on a lean basis by keeping salaries reasonable and office overhead costs extremely low.
The share structure of the stock is also attractive with only 7,929,246 shares of common stock outstanding as of last month. PuraMed is also a fully reporting company, meaning the company must be audited by a PCAOB registered public accounting firm and must comply with the requirements of Sarbanes-Oxley. These requirements allow for greater transparency and the ability to attract a larger investor audience, subsequently enhancing shareholder value and providing greater access to capital for further growth.
With a management team bringing more than 80 years of combined industry experience, a product line addressing major healthcare needs with many competitive advantages, and a well thought-out business plan, this company is well on its way to success in the multi-billion dollar OTC medicine market. Continue to watch this company as it strives to dramatically improve the quality of life for millions of Americans.
About the Company
PuraMed was established to capture two unique opportunities. The first is to build a substantial and profitable business, rapidly, beginning with three products developed by its founders: LipiGesic™ M (for acute relief of migraine headaches), LipiGesic™ H(for acute relief of tension headaches) and PuraMed™ PM (for insomnia). Each of these is effective and addresses a very large OTC consumer market, collectively well over $2 billion in the U.S. Each product will be unique in its class.
RALLYYY ..
MARKET-CAP OF 18 Mio$ IS STILL WAYYYYY UNDERVALUED ..
Get on board before the stock gets discovered . 6 US$++ soon !!!
Puramed (PMBS.OB)
Market Cap: 18 M$
Price: 1,45 $
Shares Out : 11,99 M (8,6 M Shares held by Insider)
Float : 2,6 Million
Why Puramed Bioscience Inc. (PMBS.OB) Should Be On Your Radar
Monday, April 6th, 2009
PuraMed Bioscience, Inc. is a pharmaceutical company focused on developing and marketing a line of new, non-prescription medicines. These products target major consumer health needs, including the treatment of headaches, insomnia, and general pain. The company aims launch its first retail products within six months, and then leverage that success to become a leader in the Over-the-Counter (OTC) medicine marketplace.
Although PuraMed Bioscience is entering into a competitive market, the company’s products promise to bring innovation to the industry, allowing for faster absorption into the blood stream, greater effectiveness, fewer side effects, and lower dosage requirements. The first three products the company plans to introduce include: LipiGesic M™ (for acute relief of migraine headaches), LipiGesic H™ (for acute relief of tension headaches) and LipiGesic PM™ (for insomnia).
PuraMed is already sufficiently funded via private funding and ready to move forward with the execution of its comprehensive business plan. Recently BrokerBank analyst Philip Wright, CFA initiated investment coverage of the company and has rated the company as a “speculative buy”. Wright praised the company for running on a lean basis by keeping salaries reasonable and office overhead costs extremely low.
The share structure of the stock is also attractive with only 7,929,246 shares of common stock outstanding as of last month. PuraMed is also a fully reporting company, meaning the company must be audited by a PCAOB registered public accounting firm and must comply with the requirements of Sarbanes-Oxley. These requirements allow for greater transparency and the ability to attract a larger investor audience, subsequently enhancing shareholder value and providing greater access to capital for further growth.
With a management team bringing more than 80 years of combined industry experience, a product line addressing major healthcare needs with many competitive advantages, and a well thought-out business plan, this company is well on its way to success in the multi-billion dollar OTC medicine market. Continue to watch this company as it strives to dramatically improve the quality of life for millions of Americans.
About the Company
PuraMed was established to capture two unique opportunities. The first is to build a substantial and profitable business, rapidly, beginning with three products developed by its founders: LipiGesic™ M (for acute relief of migraine headaches), LipiGesic™ H(for acute relief of tension headaches) and PuraMed™ PM (for insomnia). Each of these is effective and addresses a very large OTC consumer market, collectively well over $2 billion in the U.S. Each product will be unique in its class.
RALLLLYYYYYYYYYYYYYYYYYYYYYYYYY
UP 60% AND STILL VERY VERY CHEAP WOHOOOHOOOO
RALLLLLLLLLLLLLLLLYYYY
UP 60% WOHOHOHO
Get on board before the stock gets discovered . 6 US$+ soon !!!
Puramed (PMBS.OB)
Market Cap: 8,7 M$
Price: 0,73 $
Shares Out : 11,99 M (8,6 M Shares held by Insider)
Float : 2,6 Million
Why Puramed Bioscience Inc. (PMBS.OB) Should Be On Your Radar
Monday, April 6th, 2009
PuraMed Bioscience, Inc. is a pharmaceutical company focused on developing and marketing a line of new, non-prescription medicines. These products target major consumer health needs, including the treatment of headaches, insomnia, and general pain. The company aims launch its first retail products within six months, and then leverage that success to become a leader in the Over-the-Counter (OTC) medicine marketplace.
Although PuraMed Bioscience is entering into a competitive market, the company’s products promise to bring innovation to the industry, allowing for faster absorption into the blood stream, greater effectiveness, fewer side effects, and lower dosage requirements. The first three products the company plans to introduce include: LipiGesic M™ (for acute relief of migraine headaches), LipiGesic H™ (for acute relief of tension headaches) and LipiGesic PM™ (for insomnia).
PuraMed is already sufficiently funded via private funding and ready to move forward with the execution of its comprehensive business plan. Recently BrokerBank analyst Philip Wright, CFA initiated investment coverage of the company and has rated the company as a “speculative buy”. Wright praised the company for running on a lean basis by keeping salaries reasonable and office overhead costs extremely low.
The share structure of the stock is also attractive with only 7,929,246 shares of common stock outstanding as of last month. PuraMed is also a fully reporting company, meaning the company must be audited by a PCAOB registered public accounting firm and must comply with the requirements of Sarbanes-Oxley. These requirements allow for greater transparency and the ability to attract a larger investor audience, subsequently enhancing shareholder value and providing greater access to capital for further growth.
With a management team bringing more than 80 years of combined industry experience, a product line addressing major healthcare needs with many competitive advantages, and a well thought-out business plan, this company is well on its way to success in the multi-billion dollar OTC medicine market. Continue to watch this company as it strives to dramatically improve the quality of life for millions of Americans.
About the Company
PuraMed was established to capture two unique opportunities. The first is to build a substantial and profitable business, rapidly, beginning with three products developed by its founders: LipiGesic™ M (for acute relief of migraine headaches), LipiGesic™ H(for acute relief of tension headaches) and PuraMed™ PM (for insomnia). Each of these is effective and addresses a very large OTC consumer market, collectively well over $2 billion in the U.S. Each product will be unique in its class.
CHART LOOKS VERY BULLISH ..
2-3 by next week...
http://quote.barchart.com/texpert.asp?sym=PMBS
Puramed (Pmbs.ob)
Market Cap: 9,3 M$
Price: 0,77 $
Shares Out : 11,99 M (8,6 M Shares held by Insider)
Float : 2,6 Million
Why Puramed Bioscience Inc. (PMBS.OB) Should Be On Your Radar
Monday, April 6th, 2009
PuraMed Bioscience, Inc. is a pharmaceutical company focused on developing and marketing a line of new, non-prescription medicines. These products target major consumer health needs, including the treatment of headaches, insomnia, and general pain. The company aims launch its first retail products within six months, and then leverage that success to become a leader in the Over-the-Counter (OTC) medicine marketplace.
Although PuraMed Bioscience is entering into a competitive market, the company’s products promise to bring innovation to the industry, allowing for faster absorption into the blood stream, greater effectiveness, fewer side effects, and lower dosage requirements. The first three products the company plans to introduce include: LipiGesic M™ (for acute relief of migraine headaches), LipiGesic H™ (for acute relief of tension headaches) and LipiGesic PM™ (for insomnia).
PuraMed is already sufficiently funded via private funding and ready to move forward with the execution of its comprehensive business plan. Recently BrokerBank analyst Philip Wright, CFA initiated investment coverage of the company and has rated the company as a “speculative buy”. Wright praised the company for running on a lean basis by keeping salaries reasonable and office overhead costs extremely low.
The share structure of the stock is also attractive with only 7,929,246 shares of common stock outstanding as of last month. PuraMed is also a fully reporting company, meaning the company must be audited by a PCAOB registered public accounting firm and must comply with the requirements of Sarbanes-Oxley. These requirements allow for greater transparency and the ability to attract a larger investor audience, subsequently enhancing shareholder value and providing greater access to capital for further growth.
With a management team bringing more than 80 years of combined industry experience, a product line addressing major healthcare needs with many competitive advantages, and a well thought-out business plan, this company is well on its way to success in the multi-billion dollar OTC medicine market. Continue to watch this company as it strives to dramatically improve the quality of life for millions of Americans.
About the Company
PuraMed was established to capture two unique opportunities. The first is to build a substantial and profitable business, rapidly, beginning with three products developed by its founders: LipiGesic™ M (for acute relief of migraine headaches), LipiGesic™ H(for acute relief of tension headaches) and PuraMed™ PM (for insomnia). Each of these is effective and addresses a very large OTC consumer market, collectively well over $2 billion in the U.S. Each product will be unique in its class.
PMBS IS ON THE MOVE AGAIN
Get on board before the stock gets discovered !
Puramed (Pmbs.ob)
Market Cap: 9,3 M$
Price: 0,77 $
Shares Out : 11,99 M ( 8,6 M Shares held by Insider)
Float : 2,6 Million
Why Puramed Bioscience Inc. (PMBS.OB) Should Be On Your Radar
Monday, April 6th, 2009
PuraMed Bioscience, Inc. is a pharmaceutical company focused on developing and marketing a line of new, non-prescription medicines. These products target major consumer health needs, including the treatment of headaches, insomnia, and general pain. The company aims launch its first retail products within six months, and then leverage that success to become a leader in the Over-the-Counter (OTC) medicine marketplace.
Although PuraMed Bioscience is entering into a competitive market, the company’s products promise to bring innovation to the industry, allowing for faster absorption into the blood stream, greater effectiveness, fewer side effects, and lower dosage requirements. The first three products the company plans to introduce include: LipiGesic M™ (for acute relief of migraine headaches), LipiGesic H™ (for acute relief of tension headaches) and LipiGesic PM™ (for insomnia).
PuraMed is already sufficiently funded via private funding and ready to move forward with the execution of its comprehensive business plan. Recently BrokerBank analyst Philip Wright, CFA initiated investment coverage of the company and has rated the company as a “speculative buy”. Wright praised the company for running on a lean basis by keeping salaries reasonable and office overhead costs extremely low.
The share structure of the stock is also attractive with only 7,929,246 shares of common stock outstanding as of last month. PuraMed is also a fully reporting company, meaning the company must be audited by a PCAOB registered public accounting firm and must comply with the requirements of Sarbanes-Oxley. These requirements allow for greater transparency and the ability to attract a larger investor audience, subsequently enhancing shareholder value and providing greater access to capital for further growth.
With a management team bringing more than 80 years of combined industry experience, a product line addressing major healthcare needs with many competitive advantages, and a well thought-out business plan, this company is well on its way to success in the multi-billion dollar OTC medicine market. Continue to watch this company as it strives to dramatically improve the quality of life for millions of Americans.
About the Company
PuraMed was established to capture two unique opportunities. The first is to build a substantial and profitable business, rapidly, beginning with three products developed by its founders: LipiGesic™ M (for acute relief of migraine headaches), LipiGesic™ H(for acute relief of tension headaches) and PuraMed™ PM (for insomnia). Each of these is effective and addresses a very large OTC consumer market, collectively well over $2 billion in the U.S. Each product will be unique in its class.
PMBS IS ON THE MOVE AGAIN
Get on board before the stock gets discovered !
Puramed (Pmbs.ob)
Market Cap: 9,6 M$
Price: 0,76 $
Shares Out : 11,99 Million (8,6M Shares held by Insider)
Float : 2,6 Million
Why Puramed Bioscience Inc. (PMBS.OB) Should Be On Your Radar
Monday, April 6th, 2009
PuraMed Bioscience, Inc. is a pharmaceutical company focused on developing and marketing a line of new, non-prescription medicines. These products target major consumer health needs, including the treatment of headaches, insomnia, and general pain. The company aims launch its first retail products within six months, and then leverage that success to become a leader in the Over-the-Counter (OTC) medicine marketplace.
Although PuraMed Bioscience is entering into a competitive market, the company’s products promise to bring innovation to the industry, allowing for faster absorption into the blood stream, greater effectiveness, fewer side effects, and lower dosage requirements. The first three products the company plans to introduce include: LipiGesic M™ (for acute relief of migraine headaches), LipiGesic H™ (for acute relief of tension headaches) and LipiGesic PM™ (for insomnia).
PuraMed is already sufficiently funded via private funding and ready to move forward with the execution of its comprehensive business plan. Recently BrokerBank analyst Philip Wright, CFA initiated investment coverage of the company and has rated the company as a “speculative buy”. Wright praised the company for running on a lean basis by keeping salaries reasonable and office overhead costs extremely low.
The share structure of the stock is also attractive with only 7,929,246 shares of common stock outstanding as of last month. PuraMed is also a fully reporting company, meaning the company must be audited by a PCAOB registered public accounting firm and must comply with the requirements of Sarbanes-Oxley. These requirements allow for greater transparency and the ability to attract a larger investor audience, subsequently enhancing shareholder value and providing greater access to capital for further growth.
With a management team bringing more than 80 years of combined industry experience, a product line addressing major healthcare needs with many competitive advantages, and a well thought-out business plan, this company is well on its way to success in the multi-billion dollar OTC medicine market. Continue to watch this company as it strives to dramatically improve the quality of life for millions of Americans.
About the Company
PuraMed was established to capture two unique opportunities. The first is to build a substantial and profitable business, rapidly, beginning with three products developed by its founders: LipiGesic™ M (for acute relief of migraine headaches), LipiGesic™ H(for acute relief of tension headaches) and PuraMed™ PM (for insomnia). Each of these is effective and addresses a very large OTC consumer market, collectively well over $2 billion in the U.S. Each product will be unique in its class.
UP 35% BOOOOYAAAAHH
STILL A VERY VERY BIG OPPORTUNITY .....
Puramed (PMBS.OB)
Market Cap: 9,4 Mio$
Price: 0,80 $
Shares Out : 11,99 Million (8,6M Shares held by Insider)
Float : 2,6 Million
Why Puramed Bioscience Inc. (PMBS.OB) Should Be On Your Radar
Monday, April 6th, 2009
PuraMed Bioscience, Inc. is a pharmaceutical company focused on developing and marketing a line of new, non-prescription medicines. These products target major consumer health needs, including the treatment of headaches, insomnia, and general pain. The company aims launch its first retail products within six months, and then leverage that success to become a leader in the Over-the-Counter (OTC) medicine marketplace.
Although PuraMed Bioscience is entering into a competitive market, the company’s products promise to bring innovation to the industry, allowing for faster absorption into the blood stream, greater effectiveness, fewer side effects, and lower dosage requirements. The first three products the company plans to introduce include: LipiGesic M™ (for acute relief of migraine headaches), LipiGesic H™ (for acute relief of tension headaches) and LipiGesic PM™ (for insomnia).
PuraMed is already sufficiently funded via private funding and ready to move forward with the execution of its comprehensive business plan. Recently BrokerBank analyst Philip Wright, CFA initiated investment coverage of the company and has rated the company as a “speculative buy”. Wright praised the company for running on a lean basis by keeping salaries reasonable and office overhead costs extremely low.
The share structure of the stock is also attractive with only 7,929,246 shares of common stock outstanding as of last month. PuraMed is also a fully reporting company, meaning the company must be audited by a PCAOB registered public accounting firm and must comply with the requirements of Sarbanes-Oxley. These requirements allow for greater transparency and the ability to attract a larger investor audience, subsequently enhancing shareholder value and providing greater access to capital for further growth.
With a management team bringing more than 80 years of combined industry experience, a product line addressing major healthcare needs with many competitive advantages, and a well thought-out business plan, this company is well on its way to success in the multi-billion dollar OTC medicine market. Continue to watch this company as it strives to dramatically improve the quality of life for millions of Americans.
About the Company
PuraMed was established to capture two unique opportunities. The first is to build a substantial and profitable business, rapidly, beginning with three products developed by its founders: LipiGesic™ M (for acute relief of migraine headaches), LipiGesic™ H(for acute relief of tension headaches) and PuraMed™ PM (for insomnia). Each of these is effective and addresses a very large OTC consumer market, collectively well over $2 billion in the U.S. Each product will be unique in its class.
UP 35% BOOOOOM
STILL A VERY VERY HUGE OPPORTUNITY !!!!
Puramed (PMBS.OB)
Market Cap: 9,4 Mio$
Price: 0,80 $
Shares Out : 11,99 Million (8,6M Shares held by Insider)
Float : 2,6 Million
Why Puramed Bioscience Inc. (PMBS.OB) Should Be On Your Radar
Monday, April 6th, 2009
PuraMed Bioscience, Inc. is a pharmaceutical company focused on developing and marketing a line of new, non-prescription medicines. These products target major consumer health needs, including the treatment of headaches, insomnia, and general pain. The company aims launch its first retail products within six months, and then leverage that success to become a leader in the Over-the-Counter (OTC) medicine marketplace.
Although PuraMed Bioscience is entering into a competitive market, the company’s products promise to bring innovation to the industry, allowing for faster absorption into the blood stream, greater effectiveness, fewer side effects, and lower dosage requirements. The first three products the company plans to introduce include: LipiGesic M™ (for acute relief of migraine headaches), LipiGesic H™ (for acute relief of tension headaches) and LipiGesic PM™ (for insomnia).
PuraMed is already sufficiently funded via private funding and ready to move forward with the execution of its comprehensive business plan. Recently BrokerBank analyst Philip Wright, CFA initiated investment coverage of the company and has rated the company as a “speculative buy”. Wright praised the company for running on a lean basis by keeping salaries reasonable and office overhead costs extremely low.
The share structure of the stock is also attractive with only 7,929,246 shares of common stock outstanding as of last month. PuraMed is also a fully reporting company, meaning the company must be audited by a PCAOB registered public accounting firm and must comply with the requirements of Sarbanes-Oxley. These requirements allow for greater transparency and the ability to attract a larger investor audience, subsequently enhancing shareholder value and providing greater access to capital for further growth.
With a management team bringing more than 80 years of combined industry experience, a product line addressing major healthcare needs with many competitive advantages, and a well thought-out business plan, this company is well on its way to success in the multi-billion dollar OTC medicine market. Continue to watch this company as it strives to dramatically improve the quality of life for millions of Americans.
About the Company
PuraMed was established to capture two unique opportunities. The first is to build a substantial and profitable business, rapidly, beginning with three products developed by its founders: LipiGesic™ M (for acute relief of migraine headaches), LipiGesic™ H(for acute relief of tension headaches) and PuraMed™ PM (for insomnia). Each of these is effective and addresses a very large OTC consumer market, collectively well over $2 billion in the U.S. Each product will be unique in its class.
RALLLYYYYYYYYY
Market-cap of 9 Mio§ is still a joke
Get on board before the stock gets discovered !
Puramed (Pmbs.ob)
Market Cap: 5,9 M$
Price: 0,50 $
Shares Out : 11,99 Million (8,6M Shares held by Insider)
Float : 2,6 Million
Why Puramed Bioscience Inc. (PMBS.OB) Should Be On Your Radar
Monday, April 6th, 2009
PuraMed Bioscience, Inc. is a pharmaceutical company focused on developing and marketing a line of new, non-prescription medicines. These products target major consumer health needs, including the treatment of headaches, insomnia, and general pain. The company aims launch its first retail products within six months, and then leverage that success to become a leader in the Over-the-Counter (OTC) medicine marketplace.
Although PuraMed Bioscience is entering into a competitive market, the company’s products promise to bring innovation to the industry, allowing for faster absorption into the blood stream, greater effectiveness, fewer side effects, and lower dosage requirements. The first three products the company plans to introduce include: LipiGesic M™ (for acute relief of migraine headaches), LipiGesic H™ (for acute relief of tension headaches) and LipiGesic PM™ (for insomnia).
PuraMed is already sufficiently funded via private funding and ready to move forward with the execution of its comprehensive business plan. Recently BrokerBank analyst Philip Wright, CFA initiated investment coverage of the company and has rated the company as a “speculative buy”. Wright praised the company for running on a lean basis by keeping salaries reasonable and office overhead costs extremely low.
The share structure of the stock is also attractive with only 7,929,246 shares of common stock outstanding as of last month. PuraMed is also a fully reporting company, meaning the company must be audited by a PCAOB registered public accounting firm and must comply with the requirements of Sarbanes-Oxley. These requirements allow for greater transparency and the ability to attract a larger investor audience, subsequently enhancing shareholder value and providing greater access to capital for further growth.
With a management team bringing more than 80 years of combined industry experience, a product line addressing major healthcare needs with many competitive advantages, and a well thought-out business plan, this company is well on its way to success in the multi-billion dollar OTC medicine market. Continue to watch this company as it strives to dramatically improve the quality of life for millions of Americans.
About the Company
PuraMed was established to capture two unique opportunities. The first is to build a substantial and profitable business, rapidly, beginning with three products developed by its founders: LipiGesic™ M (for acute relief of migraine headaches), LipiGesic™ H(for acute relief of tension headaches) and PuraMed™ PM (for insomnia). Each of these is effective and addresses a very large OTC consumer market, collectively well over $2 billion in the U.S. Each product will be unique in its class.
Market-Cap 6 Mio US$= Lifetime Opportunity !
Why Puramed Bioscience Inc. (PMBS.OB) Should Be On Your Radar
PuraMed Bioscience, Inc. is a pharmaceutical company focused on developing and marketing a line of new, non-prescription medicines. These products target major consumer health needs, including the treatment of headaches, insomnia, and general pain. The company aims launch its first retail products within six months, and then leverage that success to become a leader in the Over-the-Counter (OTC) medicine marketplace.
Although PuraMed Bioscience is entering into a competitive market, the company’s products promise to bring innovation to the industry, allowing for faster absorption into the blood stream, greater effectiveness, fewer side effects, and lower dosage requirements. The first three products the company plans to introduce include: LipiGesic M™ (for acute relief of migraine headaches), LipiGesic H™ (for acute relief of tension headaches) and LipiGesic PM™ (for insomnia).
PuraMed is already sufficiently funded via private funding and ready to move forward with the execution of its comprehensive business plan. Recently BrokerBank analyst Philip Wright, CFA initiated investment coverage of the company and has rated the company as a “speculative buy”. Wright praised the company for running on a lean basis by keeping salaries reasonable and office overhead costs extremely low.
The share structure of the stock is also attractive with only 7,929,246 shares of common stock outstanding as of last month. PuraMed is also a fully reporting company, meaning the company must be audited by a PCAOB registered public accounting firm and must comply with the requirements of Sarbanes-Oxley. These requirements allow for greater transparency and the ability to attract a larger investor audience, subsequently enhancing shareholder value and providing greater access to capital for further growth.
With a management team bringing more than 80 years of combined industry experience, a product line addressing major healthcare needs with many competitive advantages, and a well thought-out business plan, this company is well on its way to success in the multi-billion dollar OTC medicine market. Continue to watch this company as it strives to dramatically improve the quality of life for millions of Americans.
Market-Cap 6 Mio US$ =Lifetime Opportunity !!
Why Puramed Bioscience Inc. (PMBS.OB) Should Be On Your Radar
PuraMed Bioscience, Inc. is a pharmaceutical company focused on developing and marketing a line of new, non-prescription medicines. These products target major consumer health needs, including the treatment of headaches, insomnia, and general pain. The company aims launch its first retail products within six months, and then leverage that success to become a leader in the Over-the-Counter (OTC) medicine marketplace.
Although PuraMed Bioscience is entering into a competitive market, the company’s products promise to bring innovation to the industry, allowing for faster absorption into the blood stream, greater effectiveness, fewer side effects, and lower dosage requirements. The first three products the company plans to introduce include: LipiGesic M™ (for acute relief of migraine headaches), LipiGesic H™ (for acute relief of tension headaches) and LipiGesic PM™ (for insomnia).
PuraMed is already sufficiently funded via private funding and ready to move forward with the execution of its comprehensive business plan. Recently BrokerBank analyst Philip Wright, CFA initiated investment coverage of the company and has rated the company as a “speculative buy”. Wright praised the company for running on a lean basis by keeping salaries reasonable and office overhead costs extremely low.
The share structure of the stock is also attractive with only 7,929,246 shares of common stock outstanding as of last month. PuraMed is also a fully reporting company, meaning the company must be audited by a PCAOB registered public accounting firm and must comply with the requirements of Sarbanes-Oxley. These requirements allow for greater transparency and the ability to attract a larger investor audience, subsequently enhancing shareholder value and providing greater access to capital for further growth.
With a management team bringing more than 80 years of combined industry experience, a product line addressing major healthcare needs with many competitive advantages, and a well thought-out business plan, this company is well on its way to success in the multi-billion dollar OTC medicine market. Continue to watch this company as it strives to dramatically improve the quality of life for millions of Americans.
Migraine is a Billion Dollar Market !!
Market Cap of 5,9 M$ is wayyyyyy undervalued ...
EU-Approval soon
Market-cap only 10,6 M$ ..
EU-Approval soon
Market-cap 10,6 M$
Huge upside potential here
THIS UNDISCOVERED STOCK HAS TREMENDOUS UPSIDE POTENTIAL ..PLEASE DO YOUR OWN DD !!!!
GLTA ...
Puramed (Pmbs.ob)
Market Cap: 5,9 M$
Price: 0,50 $
Shares Out : 11,99 Million
Float : 2,6 Million
from their Homepage:
When does PuraMed BioScience expect to launch its first commercial product and begin generating revenue?
PuraMed BioScience will launch its LipiGesic M migraine product via a direct-response infomercial scheduled for broadcast in October 2009.
--------
When do you anticipate generating revenue?
PuraMed BioScience expects to generate revenue in October 2009, which corresponds to the date the direct response commercial is scheduled to be televised.
--------
When do you expect to launch first product in retail or commercial environment?
PuraMed BioScience will approach retailers within 60-days from the initial airing of our LipiGesic M migraine product direct response television commercial.
----------
Do PuraMed BioScience products require FDA approval?
Unlike prescription drugs or medications, non-prescription healthcare remedies such as PuraMed products do not require FDA approval prior to entering the market. PuraMed products are nonetheless subject to substantial FDA and other federal regulations governing their use, labeling, advertising, manufacturing and ingredients. PuraMed BioScience believes that its current and proposed development, formulation, marketing and other practices and procedures will comply fully with all governmental regulations applicable to PuraMed products.
---------
How many products does PuraMed BioScience have in progress?
LipiGesic M for the relief of migraine headaches is the first PuraMed product that will be introduced to the market. Following its entrance into the market, two other products, LipiGesic PM for insomnia and LipiGesic H for tension headaches, will be developed and introduced. There are also product formulations for relief from canker sores, restless-leg syndrome, nighttime-reflux disorders, smoking cessation, and weight loss that will soon follow.
------------------------------------
With a management team bringing more than 80 years of combined industry experience, a product line addressing major healthcare needs with many competitive advantages, and a well thought-out business plan, this company is well on its way to success in the multi-billion dollar OTC medicine market. Continue to watch this company as it strives to dramatically improve the quality of life for millions of Americans.
About the Company
PuraMed was established to capture two unique opportunities. The first is to build a substantial and profitable business, rapidly, beginning with three products developed by its founders: LipiGesic™ M (for acute relief of migraine headaches), LipiGesic™ H(for acute relief of tension headaches) and PuraMed™ PM (for insomnia). Each of these is effective and addresses a very large OTC consumer market, collectively well over $2 billion in the U.S. Each product will be unique in its class.
Good news today !!!!
RALLY WILL START SOON.MARK THIS POST
THIS STOCK WILL GO OVER 10$ EASILY..PURAMED IS FLYING UNDER RADAR !!
If you do your homework, you will clearly see that this stock will rise rapidly as soon as it gets noticed.
Good Luck !!!!!
Puramed (Pmbs.ob)
Market Cap: 5,9 M$
Price: 0,50 $
Shares Out : 11,99 Million
Float : 2,6 Million
from their Homepage:
When does PuraMed BioScience expect to launch its first commercial product and begin generating revenue?
PuraMed BioScience will launch its LipiGesic M migraine product via a direct-response infomercial scheduled for broadcast in October 2009.
--------
When do you anticipate generating revenue?
PuraMed BioScience expects to generate revenue in October 2009, which corresponds to the date the direct response commercial is scheduled to be televised.
--------
When do you expect to launch first product in retail or commercial environment?
PuraMed BioScience will approach retailers within 60-days from the initial airing of our LipiGesic M migraine product direct response television commercial.
----------
Do PuraMed BioScience products require FDA approval?
Unlike prescription drugs or medications, non-prescription healthcare remedies such as PuraMed products do not require FDA approval prior to entering the market. PuraMed products are nonetheless subject to substantial FDA and other federal regulations governing their use, labeling, advertising, manufacturing and ingredients. PuraMed BioScience believes that its current and proposed development, formulation, marketing and other practices and procedures will comply fully with all governmental regulations applicable to PuraMed products.
---------
How many products does PuraMed BioScience have in progress?
LipiGesic M for the relief of migraine headaches is the first PuraMed product that will be introduced to the market. Following its entrance into the market, two other products, LipiGesic PM for insomnia and LipiGesic H for tension headaches, will be developed and introduced. There are also product formulations for relief from canker sores, restless-leg syndrome, nighttime-reflux disorders, smoking cessation, and weight loss that will soon follow.
With a management team bringing more than 80 years of combined industry experience, a product line addressing major healthcare needs with many competitive advantages, and a well thought-out business plan, this company is well on its way to success in the multi-billion dollar OTC medicine market. Continue to watch this company as it strives to dramatically improve the quality of life for millions of Americans.
About the Company
PuraMed was established to capture two unique opportunities. The first is to build a substantial and profitable business, rapidly, beginning with three products developed by its founders: LipiGesic™ M (for acute relief of migraine headaches), LipiGesic™ H(for acute relief of tension headaches) and PuraMed™ PM (for insomnia). Each of these is effective and addresses a very large OTC consumer market, collectively well over $2 billion in the U.S. Each product will be unique in its class.
Time to get in !!!
US Approval soon
Get in Now before its too late ..
When does PuraMed BioScience expect to launch its first commercial product and begin generating revenue?
PuraMed BioScience will launch its LipiGesic M migraine product via a direct-response infomercial scheduled for broadcast in October 2009.
How big is the non-prescription market for migraines, insomnia and tension headaches?
Currently, the non-prescription market for headache pain and sleep is approximately $2.68 billion without Walmart and approximately $3.2 with Walmart.
When do you anticipate generating revenue?
PuraMed BioScience expects to generate revenue in October 2009, which corresponds to the date the direct response commercial is scheduled to be televised.
Do PuraMed BioScience products require FDA approval?
Unlike prescription drugs or medications, non-prescription healthcare remedies such as PuraMed products do not require FDA approval prior to entering the market. PuraMed products are nonetheless subject to substantial FDA and other federal regulations governing their use, labeling, advertising, manufacturing and ingredients. PuraMed BioScience believes that its current and proposed development, formulation, marketing and other practices and procedures will comply fully with all governmental regulations applicable to PuraMed products.
How many products does PuraMed BioScience have in progress?
LipiGesic M for the relief of migraine headaches is the first PuraMed product that will be introduced to the market. Following its entrance into the market, two other products, LipiGesic PM for insomnia and LipiGesic H for tension headaches, will be developed and introduced. There are also product formulations for relief from canker sores, restless-leg syndrome, nighttime-reflux disorders, smoking cessation, and weight loss that will soon follow.
WHAT A HUGE OPPORTUNITY !!!
If you do your homework, you will clearly see that this stock will rise rapidly as soon as it gets noticed.
Please do your own Research .GLTA
Puramed (Pmbs.ob)
Marktkap: 5,9 M$
Kurs: 0,50 $
Shares Out : 11,99 Million
Float : 2,6 Million
from Homepage:
When does PuraMed BioScience expect to launch its first commercial product and begin generating revenue?
PuraMed BioScience will launch its LipiGesic M migraine product via a direct-response infomercial scheduled for broadcast in October 2009.
--------
When do you anticipate generating revenue?
PuraMed BioScience expects to generate revenue in October 2009, which corresponds to the date the direct response commercial is scheduled to be televised.
--------
When do you expect to launch first product in retail or commercial environment?
PuraMed BioScience will approach retailers within 60-days from the initial airing of our LipiGesic M migraine product direct response television commercial.
----------
Do PuraMed BioScience products require FDA approval?
Unlike prescription drugs or medications, non-prescription healthcare remedies such as PuraMed products do not require FDA approval prior to entering the market. PuraMed products are nonetheless subject to substantial FDA and other federal regulations governing their use, labeling, advertising, manufacturing and ingredients. PuraMed BioScience believes that its current and proposed development, formulation, marketing and other practices and procedures will comply fully with all governmental regulations applicable to PuraMed products.
---------
How many products does PuraMed BioScience have in progress?
LipiGesic M for the relief of migraine headaches is the first PuraMed product that will be introduced to the market. Following its entrance into the market, two other products, LipiGesic PM for insomnia and LipiGesic H for tension headaches, will be developed and introduced. There are also product formulations for relief from canker sores, restless-leg syndrome, nighttime-reflux disorders, smoking cessation, and weight loss that will soon follow.
STOCk OF THE YEAR !!!!
PURAMED IS FLYING UNDER RADAR .PLEASE DO OUR OWN RESEARCH !!!
PMBS.OB
MARKET CAP OF 5,7 M$ IS A JOKE !!!
SHARES OUT ONLY 12 MILLION
APPROX:FLOAT 2,6 M
PRICE 0,49$
Check out their Presentation ..READ
http://www.puramedbioscience.com/profile.html
About the Company
PuraMed was established to capture two unique opportunities. The first is to build a substantial and profitable business, rapidly, beginning with three products developed by its founders: LipiGesic™ M (for acute relief of migraine headaches), LipiGesic™ H(for acute relief of tension headaches) and PuraMed™ PM (for insomnia). Each of these is effective and addresses a very large OTC consumer market, collectively well over $2 billion in the U.S. Each product will be unique in its class.
PuraMed BioScience Completes Production on First Direct Response TV Commercial
Company Introduces Additional Marketing Initiatives
* Press Release
* Source: PuraMed BioScience, Inc.
* On 9:00 am EDT, Tuesday October 6, 2009
PuraMed BioScience a pharmaceutical company engaged in the development and marketing of a line of revolutionary, new, non-prescription medicines targeting major consumer health needs including the treatment of migraine headaches, insomnia and tension-type headaches, under the brand name LipiGesic™, announced today that it has completed production on its first direct response television commercial.
Avalanche Creative Services, Inc. is currently working on the editing and post-production of a 120-second spot for PuraMed that features the Company’s migraine product, LipiGesic™ M. PuraMed seeks to air the commercial nationally after an initial testing phase.
In addition to unveiling its first commercial, PuraMed is announcing the launch of a social media campaign designed to build a following of its target demographic, raise awareness of the benefits of its products and provide educational and informational resources and links. The Company has also updated its website (www.PuraMedBioScience.com), including information on its social media campaign and an enhanced investor relations section.
“We strongly believe LipiGesic™ M, our non-prescription medication solution to treat migraine headaches, can help the millions of people suffering from this debilitating ailment,” said PuraMed BioScience CEO Russell Mitchell. “Our goal is to create a community of migraine sufferers and their families through our social media efforts, and provide them with key information and education on migraines. We will then have an audience that has already been introduced to the LipiGesic™ M brand as we launch our direct response commercial. We look forward to offering affordable, readily available and effective relief for migraine headaches, and are confident that this marketing strategy will prove to be a successful way to grow the LipiGesic™ brand.”
THIS IS A REAL 20 BAGGER ++ PLEASE DO OUR OWN RESEARCH !!!
PMBS.OB
MARKET CAP OF 5,7 M$ IS A JOKE !!!
SHARES OUT ONLY 12 M
APPROX.FLOAT 2,6 M
PRICE 0,49$
Check out their Presentation ..
http://www.puramedbioscience.com/profile.html
TIME TO BUY -RALLY SOON !!!
THIS STOCK IS FLYING UNDER RADAR . PURAMED WILL EXPLODE LIKE A SUPERNOVA SOON !!!!
THIS IS A REAL 20 BAGGER ++ PLEASE DO OUR OWN RESEARCH !!!
PMBS.OB
MARKET CAP OF 4,8 M$ IS A JOKE !!!
SHARES OUT ONLY 12 MILLION
PRICE 0,40$
PuraMed BioScience Completes Production on First Direct Response TV Commercial
Company Introduces Additional Marketing Initiatives
* Press Release
* Source: PuraMed BioScience, Inc.
* On 9:00 am EDT, Tuesday October 6, 2009
SCHOFIELD, Wis.--(BUSINESS WIRE)--PuraMed BioScience (OTC Bulletin Board: PMBS - News), a pharmaceutical company engaged in the development and marketing of a line of revolutionary, new, non-prescription medicines targeting major consumer health needs including the treatment of migraine headaches, insomnia and tension-type headaches, under the brand name LipiGesic™, announced today that it has completed production on its first direct response television commercial.
Avalanche Creative Services, Inc. is currently working on the editing and post-production of a 120-second spot for PuraMed that features the Company’s migraine product, LipiGesic™ M. PuraMed seeks to air the commercial nationally after an initial testing phase.
In addition to unveiling its first commercial, PuraMed is announcing the launch of a social media campaign designed to build a following of its target demographic, raise awareness of the benefits of its products and provide educational and informational resources and links. The Company has also updated its website (www.PuraMedBioScience.com), including information on its social media campaign and an enhanced investor relations section.
“We strongly believe LipiGesic™ M, our non-prescription medication solution to treat migraine headaches, can help the millions of people suffering from this debilitating ailment,” said PuraMed BioScience CEO Russell Mitchell. “Our goal is to create a community of migraine sufferers and their families through our social media efforts, and provide them with key information and education on migraines. We will then have an audience that has already been introduced to the LipiGesic™ M brand as we launch our direct response commercial. We look forward to offering affordable, readily available and effective relief for migraine headaches, and are confident that this marketing strategy will prove to be a successful way to grow the LipiGesic™ brand.”
About the Company
PuraMed was established to capture two unique opportunities. The first is to build a substantial and profitable business, rapidly, beginning with three products developed by its founders: LipiGesic™ M (for acute relief of migraine headaches), LipiGesic™ H(for acute relief of tension headaches) and PuraMed™ PM (for insomnia). Each of these is effective and addresses a very large OTC consumer market, collectively well over $2 billion in the U.S. Each product will be unique in its class.
GET IN NOW << THIS IS A REAL WINNER
MARKET CAP OF 10 M$ IS A JOKE ...
GLTA
BREAK OUT WILL HAPPEN SOON !!!
TIME TO GET IN ....